Renoprotection by Pentoxifylline and Angiotensin Receptor Blocker in Chronic Kidney Disease (CKD)

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 350 participants.

Also called NCT01377285

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 350 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT01377285
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Taiwan (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT01377285. Randomized; quadruple masking; primary purpose treatment. Start 2010-06 (registry gives no type); primary completion 2018-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Renoprotection by Pentoxifylline and Angiotensin Receptor Blocker in Chronic Kidney Disease (CKD)
Condition
Chronic Renal Failure
Intervention (Drug)
ARB
Intervention (Drug)
Pentoxifylline
Intervention (Drug)
Placebo (for Pentoxifylline)
Lead sponsor
National Taiwan University Hospital (class: other)
Collaborator
Far Eastern Memorial Hospital (class: other)
Collaborator
Mackay Memorial Hospital (class: other)
Collaborator
Taipei Medical University Hospital (class: other)
Collaborator
Shin Kong Wu Ho-Su Memorial Hospital (class: other)
Collaborator
Cathay General Hospital (class: other)

Record details

Record id
cardio:ct-nct01377285
Content hash
137f170a2991e50df8ac55754ffd1bff2047de9e54b38fca11dc11f0dc240b08